SAGE Stock Gets Boost on FDA Approval

One analyst is calling the treatment a "niche product," however

Digital Content Manager
Mar 20, 2019 at 9:37 AM
facebook X logo linkedin

The shares of SAGE Therapeutics Inc (NASDAQ:SAGE) are up 2% at $159.20, after its postpartum depression (PPD) drug, Zulresso, was approved by the Food and Drug Administration (FDA). Some experts' negative comments could be paring back further gains, including Leerink analyst Marc Goodman, who called the new treatment a "niche product" and expects sales to come in well below the current consensus estimate.

Other analysts have chimed in on SAGE, too. SunTrust Robinson lifted its target price to $210 from $203, and Stifel slashed it to $232 from $241. Despite the mixed reviews, sentiment surrounding the stock has been generally optimistic, with 10 "strong buy" ratings, one "buy," and a single "strong sell." What's more, the consensus 12-month target price of $200.44 covers territory never before charted by the equity, and is at a roughly 25% premium to current levels. 

SAGE stock has been grinding higher since its Jan. 7 bull gap. The equity has found its footing atop the 30-day moving average but some pressure from the $160 area has kept it just below its year-over-year breakeven mark. Overall, the stock is up 78% year-to-date. 

A short squeeze could be in the cards for SAGE. While short interest fell slightly the last reporting period, the 4.21 million shares sold short still represent a solid 11.3% of the stock's available float. At the equity's average daily trading volume, it would take more than five sessions to buy back these bearish bets. 


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI